Pfizer Inc (New York, NY) hasreceived FDA approval for the intravenousantifungal Eraxis for the treatmentof candidemia, a potentially life-threateningbloodstream infection, andfor the treatment of 2 other Candidainfections, peritonitis and intra-abdominalabscesses. The product also isapproved for the treatment of esophagealcandidiasis. The recommendeddose for candidemia and other Candidainfections is a single 200-mg loadingdose of Eraxis on day 1, followed by a100-mg daily dose thereafter. The recommendeddose for esophageal candidiasisis a single 100-mg loading dose of Eraxison day 1, followed by a 50-mg daily dosethereafter. Eraxis is available in 50-mgsingle-use vials of sterile, lyophilized, preservative-free powder. The companionsingle-use diluent vials contain 15 mL of20% (w/w) dehydrated alcohol in waterfor injection. For more information, visitwww.eraxisrx.com, or call 800-438-1985.